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iNTRoDUCTioN
Antidepressant treatment is one of the recommended
treatment options for patients with Major Depressive
and Anxiety Disorders. Today there is a wide variety
of drugs available, such as selective serotonin (5-HT)
reuptake inhibitors (SSRIs), selective serotonin nore-
pinephrine reuptake inhibitors (SNRIs), tricyclic an-
tidepressants (TCAs), and also atypical antipsychotics.
All these drugs function by initially increasing monoa -
mine availability – mainly serotonin (5-HT) and nore-
pinephrine (NE), but also dopamine (DA) - in the
synaptic cleft, thus triggering a series of downstream
molecular and cellular events eventually leading to
clinical response (a new class of antidepressant agents
under study target glutamatergic transmission but it
includes no licensed drugs as yet1). While efficacy is
generally comparable between different antidepressants,
treatment is by no means universally effective, especially
in the case of major depression; it is estimated that 10-
15% of patients do not respond to adequate treatment
at all, whereas 30-40% show only partial remission2,3.
Adverse effects and drug-drug interactions are other
important determinants of treatment selection4. 
voRTioXeTiNe – 
A NoveL ANTiDePReSSANT
Vortioxetine (1-[2-(2,4-dimethyl-phenylsulfanyl)-phe -
nyl]-piperazine hydrobromide, previously designated
Lu AA21004; Fig. 1) is a novel antidepressant designed
based on the hypothesis that, in addition to increasing
monoamine availability [in this case 5-HT, by inhibiting
serotonin transporter (SERT) in the same manner as
the SSRIs], 5-HT1A receptor agonism would lead to
increased efficacy, while 5-HT3 receptor antagonism
would eliminate the nausea symptoms sometimes ex-
perienced by patients using SSRIs and SNRIs. As it
turned out, vortioxetine exhibits other serotonin recep -
tor-related actions as well, such as 5-HT7 and 5-HT1D
receptor antagonism, and 5-HT1B receptor partial ag-
onism5. All these activities classify vortioxetine into
the new antidepressant class of serotonin modulators
and stimulators (SMSs) along with vilazodone, another
novel antidepressant agent6. There is also evidence
that vortioxetine can modulate neurotransmission in
several other systems, such as the norepinephrine,
dopamine, histamine, acetylcholine, γ-amino-butyric
acid (GABA) and glutamate system7.
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PhARMACoDYNAMiCS oF voRTioXeTiNe
Vortioxetine was characterized in various in vitro binding
and functional assays using recombinant cell lines ex-
pressing human and rat targets by Sanchez et al.5. In
the human assays, vortioxetine displayed the strongest
binding to SERT and the 5-HT3 receptor (Ki = 1.6
and 3.7 nM, respectively) with binding to 5-HT1A, 
5-HT7, 5-HT1B, and 5-HT1D receptors following with
approximately 10-fold lower binding affinity. Binding
to rat receptors was generally similar, with affinities
for the 5-HT7 and 5-HT1A receptors being 10- to 15-
fold weaker compared to their human counterparts.
Binding to the human norepinephrine and dopamine
transporters was significantly weaker (Ki = 113 and
1000 nM, respectively).
The activation of somatodendritic 5-HT1A receptors
has as a result the decrease of 5-HT release, which is
thought responsible for the delay of the therapeutic
effect of most antidepressants. On the other hand, a
5-HT1A agonist may rapidly lead to desensitization of
the somatodendritic 5-HT1A receptors and, at the same
time, activate postsynaptic 5-HT1A receptors that me-
diate at least part of the therapeutic actions of antide-
pressants. Thus, the therapeutic effect of vortioxetine
could also be related (in addition to its inhibiting effect
on SERT) to desensitizing the somatodendritic and
activating postsynaptic 5-HT1A receptors
8. Also, the
antagonism of 5-HT binding at 5-HT7 receptors is
known to produce an antidepressive-like effect, by en-
hancing the actions of SSRIs and the activation of post-
synaptic 5-HT1A receptors in the hippocampus
9. 5-HT3
receptor antagonism did not eliminate nausea in clinical
studies10 but may contribute to a more benign effect
of sleep architecture than other antidepressants11. Fi-
nally, the partial agonistic effect of vortioxetine at the
5-HT1B receptor could also play an important role in
its clinical effect; genetic and postmortem studies in-
dicate that mutations of this receptor subtype are im-
plicated in psychiatric disorders, including major de-
pression12.
PhARMACoKiNeTiCS oF voRTioXeTiNe
Vortioxetine shows good bioavailability after oral ad-
ministration (75%) with a Tmax of 7–8 hr and a T1/2 of
57 hr, and also shows stable plasma concentrations in
less than 2 weeks. The rate of binding to plasma proteins
is 96%13. A population pharmacokinetic meta-analysis
produced a population mean oral clearance of 32.7
L/hr and a central volume of distribution of 1970 L14.
The average T1/2 in that study was 65.8 hr. Vortioxetine
undergoes extensive biotransformation in the liver,
with approximately one-third of drug-related material
excreted in the feces, and two-thirds in the urine pri-
marily as a benzoic acid derivative (previously desig-
nated as Lu AA34443) and its glucuronide. Other phase
I biotransformation metabolites include benzylic alco-
hol, sulfoxide, and hydroxylated derivatives, with
CYP2D6 being primarily involved and CYP2C19,
CYP2C9, CYP3A4, CYP2A6, and CYP2B6 contribut-
ing to a lesser extent15. Vortioxetine does not seem to
be a P-glycoprotein (P-gp) substrate, based on exper-
iments with P-gp knock-out (KO) mice which revealed
no significant differences in plasma and brain exposures
compared to wild-type (WT) mice16. In line with the
above observations, only the co-administration of bupro-
pion – a CYP2D6 inhibitor – was able to increase the
area under the plasma concentration curve (AUC),
and the maximum plasma vortioxetine concentration
in healthy adults, whereas other CYP inhibitors or in-
ducers had no effect17. Also, in that same study bupro-
pion increased the incidence of adverse effects when
co-administered with vortioxetine, whereas the clear-
ance of vortioxetine was reduced almost by half in
CYP2D6 poor metabolizers compared to extensive
metabolizers14. On the other hand, vortioxetine pro-
duced essentially no effect on co-administered CYP3A,
CYP2C19 and CYP2D6 substrates17 or clinically sig-
nificant co-administered drugs (ethanol, diazepam,
lithium)18.
CLiNiCAL USe oF voRTioXeTiNe
Vortioxetine was approved by the FDA in September
2013 and the European Medicines Agency (EMA) in
October 2013 for the treatment of Major Depressive
Disorder. According to the Anatomical Therapeutic
Classification (ATC) system of the World Health Or-
ganization, vortioxetine is classified into the “N06AX
Other, Antidepressants” class, which includes antide-
pressants not fitting into the established classes of
SSRIs, tricyclic antidepressants and monoamine oxidase
inhibitors. Whether the multimodal activity of vortiox-
etine confers a significant therapeutic advantage com-
pared to established antidepressants is still an open
question and will need further investigation in “real
world” conditions as opposed to the clinical trials pre-
ceding the drug’s licensing. Nevertheless, according to
a meta-analysis by Citrome 19 involving a total of 34
placebo-controlled studies (eleven with vortioxetine
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and 23 with other antidepressants), vortioxetine’s ef-
ficacy in treating Major Depressive Disorder appears
similar to that of duloxetine, escitalopram, levomil-
nacipram, sertraline, venlafaxine, and vilazodone but
its overall tolerability is higher than that of the other
antidepressants, even though nausea and vomiting are
still common side effects. More specifically, vortioxetine
displayed a slightly higher number needed to treat (N-
NT) but a considerably higher number needed to harm
(NNH) compared to the aforementioned antidepres-
sants19. In a different meta-analysis involving eleven
placebo-controlled trials and open-label extension s-
tudies and a total of 5701 participants, Baldwin et al.20
concluded that vortioxetine induced less treatment-e-
mergent adverse events (TEAEs) than velnafaxine or
duloxetine; similarly Li et al.21 showed, in yet another
meta-analysis of five randomized controlled trials with
a total number of 2287 patients, that the use of vor-
tioxetine was associated with less TEAEs compared to
duloxetine. Vortioxetine does not appear to be asso-
ciated with significant effects on body weight, which
may explain the low rates of discontinuation due to ad-
verse events22. Furthermore, the effects of vortioxetine
on sexual function may also be advantageous compared
to other antidepressants, a result demonstrated also
in a randomized controlled clinical trial assessing sexual
functioning in patients with MDD receiving vortioxetine
or escitalopram22,23. Another possible advantage of
vortioxetine is its reported positive effect on cognition
(memory and executive functioning) which exceeds
that of the other antidepressants24. Additional post-
marketing studies assessing the efficacy and tolerability
profile and also data gained from pharmacovigilance
databases will show whether vortioxetine will be able
to establish itself as a first-line antidepressant option.  
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Figure 1: The chemical structure of vortioxetine
(http://www.chemspider.com/)
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ενός νέου αντικαταθλιπτικού φαρμάκου
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Περίληψη: Η βορτιοξετίνη είναι ένα νέο αντικαταθλιπτικό φάρμακο το οποίο, πέραν της αναστολής που προκαλεί στον
μεταφορέα της σεροτονίνης, αλληλεπιδρά με διάφορους τύπους υποδοχέων της σεροτονίνης και γι’ αυτό το λόγο έχει χα-
ρακτηριστεί ως διαμορφωτής και διεγέρτης των υποδοχέων της σεροτονίνης. Η παρούσα εργασία αποτελεί μια σύντομη
ανασκόπηση πρόσφατων δεδομένων σχετικών με τη φαρμακοδυναμική, τη φαρμακοκινητική και την κλινική χρήση του
φαρμάκου αυτού.  
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